Romiplostim (Nplate) coverage
Customize your policy alerts
Sign up for Aetna Policy 0768 alerts
Get alerted when Policy 0768 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna commercial medical plan coverage and medical necessity criteria for romiplostim (Nplate) across specified indications (ITP, HS-ARS, MDS, chemotherapy-induced thrombocytopenia) and prescriber requirements.
No material clinical or coverage changes in this revision.
Medical Necessity and Coverage Criteria
inv-01: Initial Therapy — ITP
Covered when the following criteria are met
Prescribed by or in consultation with a hematologist or oncologist
inv-02: Initial Therapy — HS-ARS
Covered when the following criteria are met
Applies to adults and pediatrics including term neonates; FDA approval under Animal Rule
inv-03: Initial/Continuation Therapy — MDS
Covered when the following criteria are met
Monitor for increased blast counts and potential progression to AML; use generally limited to lower‑risk MDS and select patients with refractory bleeding/transfusion dependence
inv-04: Initial and Continuation Therapy — CIT
Covered when the following criteria are met
Compendial/off-label use supported by small series reporting weekly initiation at 1–2 µg/kg with escalation to platelet targets
Continuation supports ongoing coverage when objective benefit is documented
inv-05: Continuation Therapy — ITP
Covered when any of the following continuation conditions are met
Continuation rules specify dose adjustments and monitoring per dosing guidance
inv-06: FDA-approved indications
Covered when ALL of the following are met
FDA-approved indications supported by prescribing information and Animal Rule approval for HS-ARS
inv-07: Myelodysplastic syndromes (selective use)
Use may be considered (off-label) when ALL of the following are met
Randomized trial showed platelet increases and reduced bleeding/transfusions but was discontinued early due to concerns about blasts/AML; long‑term follow‑up did not show significant increase in AML or death—use limited to select patients after risk/benefit discussion
inv-08: Chemotherapy-induced thrombocytopenia (investigational/off-label)
Consider when ALL of the following are met
Evidence consists of small retrospective series showing platelet recovery and ability to resume chemotherapy; prospective trials needed
inv-09: Aplastic anemia (limited evidence)
Consider when ALL of the following are met
Evidence is limited to small case series and reports; further study required
inv-10: Indications and evidence summaries
Clinical indications and evidence summaries present in this section
Supported by prescribing information and randomized trials
Use in MDS is off‑label and evidence is limited
FDA‑approved for pediatric ITP ≥1 year
Evidence limited to case reports and reviews
Further prospective studies required
Concomitant use of romiplostim with other thrombopoietin receptor agonists (for example, eltrombopag, avatrombopag, or lusutrombopag) or with spleen tyrosine kinase inhibitors (e.g., Tavalisse) is excluded and will not be covered. This medication must be prescribed by or in consultation with a hematologist or oncologist; requests that indicate concurrent use with the agents listed above should be denied as not eligible for coverage under this policy.
Romiplostim is not indicated by the FDA for treatment of thrombocytopenia due to myelodysplastic syndromes (MDS) or for any cause of thrombocytopenia other than chronic immune thrombocytopenia (ITP). The FDA review of early MDS experience reported possible disease progression in a subset of patients and concluded that randomized controlled studies are needed to define risks and benefits; therefore use for MDS is not an FDA-approved indication.
Use of romiplostim in MDS is considered off-label/compendial. Randomized studies in lower-risk MDS showed increases in platelet counts and reductions in bleeding events, but early discontinuation of the trial due to concerns about progression to acute myelogenous leukemia (AML) limits interpretation. Long-term follow-up data did not demonstrate a significant increase in AML or death, but romiplostim remains not FDA-approved for MDS and any use should be limited to selective situations with careful monitoring (for example, documented clinical benefit and surveillance for rising blast counts).
Aetna considers romiplostim experimental and investigational (not medically necessary) for indications where effectiveness has not been established, including: aplastic anemia, Evans syndrome, graft-versus-host disease, hepatitis C, stem cell mobilization, thrombocytopenia during pregnancy, and thrombocytopenia following allogeneic stem cell transplantation. Requests for these indications should be treated as investigational unless compelling evidence from peer-reviewed sources and compendia justify coverage.
Routine use of romiplostim in MDS is not supported. The FDA and guideline authors note that while some trials demonstrated platelet responses, early trial discontinuation over safety concerns and limited evidence mean romiplostim should not be used routinely in MDS. Consideration may be appropriate only for selected lower-risk patients with clinically significant bleeding refractory to transfusions and antifibrinolytics, and where the potential benefits outweigh the risks.
Specifically for romiplostim in MDS, routine use is not recommended based on the randomized trial in low/intermediate-1 risk patients that was stopped early for concern about leukemic progression. Although 5-year follow-up did not show a significant increase in AML or mortality, romiplostim remains an off-label option for MDS and should generally be reserved for select patients with refractory bleeding or transfusion dependence and only with close monitoring for blast increases.
Dosing, Administration, and Regimens
| Regimen | Details | Coverage status |
|---|---|---|
| {"text":"Initial dosing","status":""},{"text":"Start romiplostim 1 mcg/kg subcutaneously once weekly; adjust weekly by 1 mcg/kg increments based on platelet response to achieve and maintain platelet count ≥50 × 10^9/L; maximum weekly dose 10 mcg/kg.","status":""},{"text":"Covered","status":"covered"} | ||
| {"text":"Dose escalation","status":""},{"text":"If platelet count <50 × 10^9/L, increase dose by 1 mcg/kg weekly until target achieved (not to exceed 10 mcg/kg/week).","status":""},{"text":"Covered","status":"covered"} | ||
| {"text":"Dose reduction","status":""},{"text":"If platelet count >200 to ≤400 × 10^9/L for 2 consecutive weeks, reduce dose by 1 mcg/kg. If platelet count >400 × 10^9/L, hold dosing; resume at dose reduced by 1 mcg/kg after count falls to <200 × 10^9/L.","status":""},{"text":"Covered","status":"covered"} | ||
| {"text":"Maximum duration criteria","status":""},{"text":"Discontinue if platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum weekly dose of 10 mcg/kg.","status":""},{"text":"Covered","status":"covered"} |
| Regimen | Details | Coverage status |
|---|---|---|
| {"text":"HS-ARS single-dose regimen","status":""},{"text":"Administer a single subcutaneous injection of romiplostim 10 mcg/kg as soon as possible after suspected or confirmed exposure to radiation >2 Gy (applies to adults and pediatrics, including term neonates).","status":""},{"text":"Covered","status":"covered"} |
| Regimen | Details / institutional experience | Coverage status |
|---|---|---|
| {"text":"Supportive CIT regimen (reported series)","status":""},{"text":"Weekly subcutaneous romiplostim initiated at 1–3 μg/kg with escalation (commonly by 1 μg/kg weekly) to achieve platelet targets (eg, ≥100 × 10^9/L in cited series); in Memorial Sloan-Kettering series mean dose to recovery ~2.9 μg/kg (range 1.0–5.1 μg/kg); weekly dosing continued during chemotherapy to permit on-schedule treatment.","status":""},{"text":"Experimental","status":"experimental"} |
| Regimen | Details / trial dosing and outcomes | Coverage status |
|---|---|---|
| {"text":"MDS trial dosing (varied)","status":""},{"text":"Weekly romiplostim studied in lower‑risk MDS with varied fixed doses; early studies used cohorts receiving 300, 700, 1,000, or 1,500 μg weekly and other studies evaluated 750 μg weekly subcutaneously; extension phases allowed up to 1 year of treatment.","status":""},{"text":"Experimental","status":"experimental"} | ||
| {"text":"Safety signal and follow-up","status":""},{"text":"A randomized trial (n=250) was halted early because of concern for increased blasts/possible AML progression; a 5‑year follow-up found no significant difference in AML (12% romiplostim vs 11% placebo) or death.","status":""},{"text":"Experimental","status":"experimental"} |
| Regimen | Details / evidence summary | Coverage status |
|---|---|---|
| {"text":"Clinical trial exposure duration","status":""},{"text":"Romiplostim has been administered in clinical trials for MDS-related thrombocytopenia for up to 58 weeks (randomized study) and in extension phases up to ~1 year; evidence is limited and interpretation affected by early discontinuation of drug in pivotal trial.","status":""},{"text":"Experimental","status":"experimental"} | ||
| {"text":"Regulatory/approval status for MDS","status":""},{"text":"Romiplostim is not FDA-approved for treatment of thrombocytopenia due to myelodysplastic syndromes; use in MDS is off-label and may be considered selectively with monitoring for blast increases.","status":""},{"text":"Not covered (routine)","status":"not_covered"} |
| Regimen / indication | Population / labeling | Coverage status |
|---|---|---|
| {"text":"Chronic immune thrombocytopenia (ITP)","status":""},{"text":"FDA-approved for adults and pediatric patients 1 year of age and older with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; dosing as per ITP recommendations (start 1 mcg/kg weekly with adjustments).","status":""},{"text":"Covered","status":"covered"} |
Billing and Coding
| J2796 | Injection, romiplostim, 10 mcg [Nplate] |
| D69.3 | Immune thrombocytopenic purpura [idiopathic] |
| D69.59 | Other secondary thrombocytopenia [chemotherapy-induced thrombocytopenia] |
| D46.22 | Myelodysplastic syndrome |
| T66.XXXA | Radiation sickness, unspecified [Hematopoietic syndrome of acute radiation syndrome] |
| B17.10 | Acute hepatitis C |
| D61.01 | Other aplastic anemias and other bone marrow failure syndromes |
| T86.5 | Complications of stem cell transplant [thrombocytopenia following allogeneic stem cell transplantation] |
Prior Authorization, Documentation, and Prescriber Requirements
Prior Authorization Required
Prior authorization is required for romiplostim (HCPCS J2796).
- Prior authorization required for romiplostim (J2796).
- Prescriber specialty: must be prescribed by or in consultation with a hematologist or oncologist.
- Exclusion: Do not use concomitantly with other TPO-RAs (eltrombopag, avatrombopag, lusutrombopag) or spleen tyrosine kinase inhibitors (e.g., fostamatinib/Tavalisse).
Prior Authorization — Non‑ITP Indications
Prior authorization applies to non-ITT indications (e.g., MDS, HS-ARS, chemotherapy-induced thrombocytopenia) and these uses may be subject to additional review; MDS use is off-label and carries safety/denial risk.
- Prior authorization required for non-ITP indications (MDS, HS-ARS, CIT).
- MDS use: randomized data limited; safety concerns (potential for progression to AML) — may be denied or require detailed justification and risk/benefit documentation.
Prior Authorization — Chronic ITP (FDA‑approved criteria)
Prior authorization is required for chronic ITP and will follow FDA‑approved criteria: inadequate response or intolerance to corticosteroids, IVIG, or splenectomy and platelet count thresholds or symptomatic bleeding as specified in policy.
- ITP prerequisites: documentation of inadequate response or intolerance to corticosteroids, immunoglobulins (IVIG), or splenectomy.
- Platelet criteria: untransfused platelet count < 30 x 10^9/L prior to initiation, or 30–50 x 10^9/L at diagnosis with symptomatic bleeding or bleeding risk factors.
Denial Risk — Indication and MDS Safety Concerns
Use may be denied when the indication is not supported (e.g., thrombocytopenia due to causes other than chronic ITP) or when required prior‑therapy criteria are not met.
- Indication‑based denial risk: use for MDS or non‑ITP causes may be denied without documentation of medical necessity.
- Off‑label MDS risk: randomized evidence limited and early studies signaled potential leukemic progression — expect heightened review and possible denial for MDS without strong justification.
Documentation Required
Required clinical documentation should be submitted with the authorization request to support medical necessity.
- Diagnosis and relevant ICD‑10 code.
- For ITP: prior therapies tried (corticosteroids, IVIG, splenectomy) with dates and clinical response or intolerance.
- Baseline and recent platelet counts (untransfused) and description of bleeding symptoms or bleeding‑risk factors if platelets 30–50 x 10^9/L.
- For MDS: diagnosis plus IPSS/IPSS‑R risk classification and rationale for use given limited approval status.
- Medication history to confirm no concomitant TPO‑RAs or spleen tyrosine kinase inhibitors.
Step Therapy and Pediatric Context
Step therapy: romiplostim for ITP is reserved for patients with inadequate response or intolerance to prior therapies; however, no additional formal step limits (e.g., mandatory trial of splenectomy before use) are imposed beyond the listed prior‑therapy criteria and pediatric context.
- Step therapy for ITP: require inadequate response or intolerance to corticosteroids, IVIG, or splenectomy prior to romiplostim.
- Context: FDA labeling specifies prior use/insufficient response to corticosteroids, IVIG, or splenectomy.
- Pediatric context: guidelines favor exhausting medical therapies (corticosteroids, IVIG, TPO‑RAs) before splenectomy; splenectomy generally deferred ≥12 months of ITP.
Policy History and Administrative Links
Administrative and policy history resources: include review history, last review date, and links for definitions and review pages as part of provider resources.
- Policy effective date: 11/07/2008; Next review: 08/22/2024.
- Last review: 01/09/2024; Review history and definitions available via Aetna policy links.
Therapy Line and Salvage Use
inv-42: salvage — line-of-therapy criterion (top-level node)
Monitor for blast increases and risk of AML progression.
inv-43: salvage — line-of-therapy criterion (top-level node)
Evidence from small series supports platelet recovery and chemotherapy continuation
inv-44: salvage — line-of-therapy criterion (top-level node)
Selection should be case‑by‑case after risk/benefit assessment
Drug Background and Definitions
Romiplostim is a thrombopoiesis-stimulating peptibody that binds the thrombopoietin receptor to increase platelet production. It is FDA-approved for treatment of chronic immune thrombocytopenia (ITP) in adults and pediatric patients ≥1 year with insufficient response to corticosteroids, immunoglobulins, or splenectomy, and was granted approval under the Animal Rule to increase survival after acute high-dose radiation exposure (hematopoietic syndrome of acute radiation syndrome, HS-ARS). Key safety considerations noted in the literature include potential thrombotic events with platelet increases, loss of response possibly due to neutralizing antibodies or marrow fibrosis, and concerns about leukemic progression when used in MDS populations.
Policy History, References, and Administrative Data
Prior authorization — policy history/administrative info
The policy history section provides review dates and links to history and definitions but does not add prescriptive prior authorization steps.
- Refer to the policy main criteria for required actions; history page is informational.
Selected references that inform this policy include clinical trials and reviews of romiplostim use in ITP and MDS, FDA materials, and specialty literature. Notable citations include the FDA approval summary and related materials, randomized and long-term follow-up studies in MDS, and reviews on management of chemotherapy-induced thrombocytopenia and pediatric use (see full reference list for details).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.